- Home
- OXBR vs PHIO Comparison
OXBR vs PHIO Comparison
Compare OXBR & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXBR | PHIO |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 12.3M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | OXBR | PHIO |
|---|---|---|
| Price | $1.25 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $10.67 |
| AVG Volume (30 Days) | 12.0K | ★ 363.0K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,423,000.00 | N/A |
| Revenue This Year | $497.99 | N/A |
| Revenue Next Year | $42.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.12 | $0.97 |
| 52 Week High | $5.81 | $9.79 |
Technical Indicators
Market Signals| Indicator | OXBR | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 34.04 |
| Support Level | $1.17 | $1.00 |
| Resistance Level | $1.30 | $1.18 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 3.23 | 19.35 |
Price Performance
Historical ComparisonAbout OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.